Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00034230
DRKS00034230
Not yet recruiting
未知

Cognitive training for patients with schizophrenia in forensic psychiatry: a pilot study

VR-Klinikum Düsseldorf0 sites15 target enrollmentJune 10, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsF20Schizophrenia

Overview

Phase
未知
Intervention
Not specified
Conditions
F20
Sponsor
VR-Klinikum Düsseldorf
Enrollment
15
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 10, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
Male

Investigators

Sponsor
VR-Klinikum Düsseldorf

Eligibility Criteria

Inclusion Criteria

  • •Patients who are forensically accommodated or
  • •\- patients of the forensic aftercare outpatient clinic
  • •\- both patients capable of giving consent and patients not capable of giving consent (for the latter, the consent of the legal guardian is also obtained)
  • •\- Main diagnosis F20
  • •\- Male gender
  • •\- Age: 30 years and older
  • •\- Native speaker of German or sufficient language skills to actively participate in the cognitive training program and the neuropsychological examinations

Exclusion Criteria

  • •Physical disabilities or illnesses that prevent participation in the study (e.g. bedriddenness, blindness, deafness)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Cognitive training for schizophrenia: a randomized controlled trialSchizophrenia
JPRN-UMIN000039521Shinshu University86
Completed
Not Applicable
Cognitive Training for Patients With SchizophreniaSchizophreniaSchizoaffective DisorderOther Primary Psychotic Disorders
NCT01521026University of California, San Diego69
Active, not recruiting
Phase 1
Pharmakotherapie kognitiver Defizite bei schizophrenen Störungen – Randomisierte placebokontrollierte Doppelblindstudie mit Pergolid versus TolcaponTOCTAP (Treatment of Cognitive Deficits in Schizophrenia with Tolcapone and Pergolide) - TOCTAPDas vorliegende Projektvorhaben dient der Untersuchung, inwieweit bei Patienten mit schizophrenen Störungen neben einer bestehenden Monotherapie mit Paliperidon (Invega), dem zuletzt zugelassenen neuartigen Antipsychotikum der sog. zweiten Generation, eine additive prodopaminerge Psychopharmakotherapie mit Tolcapon (Tasmar) oder Pergolid (Parkotil) die präfrontalen kognitiven Funktionen beeinflusst.
EUCTR2008-006905-18-DERWTH Aachen University60
Completed
Not Applicable
Treatment Of Cognitive deficits in schizophrenia with Tolcapone And Pergolide
ISRCTN42412532RWTH Aachen University (Germany)60
Completed
Not Applicable
Cognitive Remediation of Schizophrenia in a Community Mental Health SettingExperimental Condition TCTControlled Condition CG
NCT01988714University of California, San Francisco112